UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 15, 2022 |
Talis Biomedical Corporation
(Exact name of Registrant as Specified in Its Charter)
Delaware | 001-40047 | 46-3122255 | ||
(State or Other Jurisdiction | (Commission File Number) | (IRS Employer | ||
|
|
|
|
|
230 Constitution Drive |
| |||
Menlo Park, California |
| 94025 | ||
(Address of Principal Executive Offices) |
| (Zip Code) | ||
Registrant’s Telephone Number, Including Area Code: (650) 433-3000 |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
| Trading |
|
|
Common Stock, $0.0001 par value per share |
| TLIS |
| The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On March 15, 2022, Talis Biomedical Corporation (the “Company”) issued a press release announcing its financial results for the fiscal year ended December 31, 2021. A copy of the press release is attached hereto as Exhibit 99.1.
The information contained under this Item 2.02, including Exhibit 99.1 attached hereto are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On March 15, 2022, the Company announced that Douglas Liu will be stepping down as the Company’s Chief Operating Officer, effective April 15, 2022. Mr. Liu will receive severance benefits in accordance with the Company’s Severance and Change in Control Plan and will enter into a separation agreement with the Company, whereby, among other things, Mr. Liu will agree to a general release of claims in favor of the Company, as well as customary confidentiality provisions. Mr. Liu’s separation from the Company is not as a result of any disagreement with the Company.
The Company presently does not intend to fill the position of Chief Operating Officer. Instead, upon Mr. Liu’s departure, his responsibilities will be transitioned to other parts of the Company’s organization, each of which will ultimately report to the Company’s Chief Executive Officer.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
| Description |
|
|
|
99.1 |
| |
104 |
| Cover Page Interactive Data File (Embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
| TALIS BIOMEDICAL CORPORATION |
|
|
|
|
Date: | March 15, 2022 | By: | /s/ J. Roger Moody, Jr. |
|
|
| J. Roger Moody, Jr. |